Recent developments highlight ARS Pharmaceuticals’ continued commercial expansion of neffy, progress in clinical trials, and financial results for Q1 2026.

• ARS Pharmaceuticals reported Q1 2026 results including a net loss of $60.6 million and continued growth in neffy prescriptions and patient usage, with approximately 29,500 new patients added in the quarter [N4][N1].
• The company expanded its U.S. sales force to 148 employees by early May 2026, including direct and co-promotion teams, to increase market penetration [N3][N2].
• Neffy has achieved approximately 90% overall commercial insurance coverage in the U.S., with 57% coverage without prior authorization and 9 Medicaid states covering the product without prior authorization, including Florida [N3][N4].
• Real-world evidence from the neffy experience program continues to support clinical equivalence to injectable epinephrine, with approximately 90% effective treatment rates reported [N3][N1].
• The Phase 2b clinical trial for chronic spontaneous urticaria patients is fully enrolled as of May 2026, with interim data anticipated in Q4 2026 and potential Phase 3 study initiation in mid-2027 [N1][N3].
• The company continues to support commercialization with direct-to-consumer marketing, virtual prescribing via getneffy.com, patient assistance programs, and partnerships with schools and advocacy groups [N3][N4].

The company’s innovative needle-free intranasal delivery of epinephrine offers a differentiated alternative to traditional injectable devices, potentially increasing patient adherence and early treatment of allergic reactions. Broad regulatory approvals and a growing commercial footprint in the U.S. and international markets support expanding patient access. Real-world data and clinical trial progress for additional indications may enhance the product’s value proposition. Strategic collaborations and a strong patent portfolio provide barriers to entry. The company’s marketing and sales expansion, insurance coverage gains, and direct-to-consumer initiatives contribute to commercial momentum.

The company faces risks typical of early-stage biopharmaceutical firms, including continued net losses and the need for substantial capital to support commercialization and clinical development. Market adoption depends on physician and patient acceptance, insurance coverage, and competitive dynamics. Manufacturing reliance on third parties may pose supply risks. Clinical trial outcomes for new indications are uncertain, and regulatory or reimbursement challenges could impact growth. The company’s credit facility imposes restrictions that may limit financial flexibility. Failure to achieve sustained profitability or meet commercial milestones could affect operational continuity.

ARS Pharmaceuticals’ moat is based on its first-mover advantage with the only FDA and European Commission-approved needle-free intranasal epinephrine product, protected by a robust global patent portfolio extending to 2038. The product addresses significant unmet needs in epinephrine delivery by eliminating needle-related apprehension and improving ease of use and portability, which may increase patient adherence and early administration. The company’s extensive commercialization infrastructure, broad insurance coverage, and strategic collaborations for global markets further support competitive positioning. Real-world evidence and clinical data reinforce product differentiation. However, reliance on third-party manufacturers and the need for continued regulatory and commercial execution are factors to monitor.

• Commercial Adoption Risk: Market acceptance of neffy depends on physician prescribing behavior, patient adherence, and insurance coverage dynamics, which may vary and impact sales growth.
• Clinical Development Risk: Ongoing and future clinical trials for additional indications carry inherent uncertainties in timing, costs, and outcomes that could affect product pipeline and valuation.
• Manufacturing and Supply Risk: Dependence on third-party manufacturers for production introduces risks related to supply chain disruptions, quality control, and regulatory compliance.
• Financial and Capital Risk: The company has incurred significant net losses and relies on available cash, credit facilities, and capital markets to fund operations, with restrictions on additional indebtedness potentially limiting financial flexibility.
• Regulatory and Reimbursement Risk: Changes in regulatory requirements or delays in obtaining or maintaining approvals, as well as challenges in securing favorable reimbursement, could adversely affect commercialization efforts.

• ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions including anaphylaxis [S1][S2].
• Neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, also approved in the UK, Japan, Australia, China, and Canada, representing a new delivery method for epinephrine in over 35 years [S1][S2].
• Neffy uses a proprietary composition of epinephrine with an absorption enhancer called Intravail, enabling safe intranasal delivery at low doses comparable to approved injectable products [S1][S2].
• The company targets a significant market opportunity in the U.S. with approximately 6.5 million patients prescribed epinephrine autoinjectors and an estimated addressable market of $1.8 billion in annual U.S. net sales based on 3.2 million active prescription fills [S1][S2].
• As of Q1 2026, more than 28,000 healthcare providers have prescribed neffy, with about 120,000 patients using it in the U.S., including approximately 29,500 added in Q1 2026 [S2].
• ARS Pharma has a direct U.S. sales force of approximately 148 employees as of May 2026, including 106 ARS Pharma employees and about 80 co-promotion sales reps via partner ALK U.S. [S2].
• The company supports commercialization with branded direct-to-consumer marketing, virtual prescriber website getneffy.com, patient assistance programs, and partnerships with advocacy groups and schools [S1][S2].
• Neffy has broad insurance coverage in the U.S., with approximately 90% overall commercial coverage (including plans requiring prior authorization), about 57% coverage without prior authorization, and 9 Medicaid states covering neffy without prior authorization as of Q1 2026 [S2].
• The company has licensing and collaboration agreements for neffy commercialization outside the U.S. with partners including ALK (Canada, UK, EU), Alfresa (Japan), Pediatrix (China), and Seqirus (Australia/New Zealand) [S1][S2].
• Real-world data from the neffy experience program and other sources support that neffy delivers similar treatment response rates (~90%) as injectable epinephrine for anaphylaxis [S1][S2].
• ARS Pharma is conducting a Phase 2b clinical trial for chronic spontaneous urticaria patients with interim data anticipated in Q4 2026 and potential Phase 3 pivotal study initiation in mid-2027 [S1][S2].
• The company owns a global intellectual property portfolio with patents on neffy and intranasal epinephrine technology expected to expire in 2038 [S1].
• ARS Pharma does not own manufacturing facilities and relies on third-party manufacturers compliant with cGMP for production of neffy [S2].
• Financial snapshot as of March 31, 2026: cash and equivalents $24.3M, short-term investments $176.6M, current assets $245.2M, current liabilities $49.6M, current ratio 4.94, cash ratio 4.05 [S2].
• Net loss for Q1 2026 was $60.6 million with basic and diluted EPS of -$0.61 per share [S2].
• The company has incurred net losses since inception and had an accumulated deficit of $355.2 million as of March 31, 2026 [S2].
• ARS Pharma has a $250 million credit facility entered in September 2025 with RA Capital and OMERS affiliates, which restricts additional indebtedness and certain transactions without lender consent [S2].
• The company’s management team has extensive experience in pharmaceutical development and commercialization, including nasal spray products such as NARCAN and VALTOCO [S1].
• ARS Pharma’s commercialization strategy includes expanding sales force reach, increasing payor coverage, direct-to-consumer marketing, and leveraging virtual prescribing to reduce physician and patient burden [S1][S2].
• The company’s neffy product has a shelf life of 24-30 months at room temperature and improved stability at high temperatures compared to injectable epinephrine products [S1].